152 related articles for article (PubMed ID: 11926629)
21. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
Watson DJ; Harper SE; Zhao PL; Quan H; Bolognese JA; Simon TJ
Arch Intern Med; 2000 Oct; 160(19):2998-3003. PubMed ID: 11041909
[TBL] [Abstract][Full Text] [Related]
22. Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
Muratore L; Ventura M; Calogiuri G; Calcagnile F; Quarta E; Muratore M; Ferrannini A
Ann Allergy Asthma Immunol; 2007 Feb; 98(2):168-71. PubMed ID: 17304885
[TBL] [Abstract][Full Text] [Related]
23. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
[TBL] [Abstract][Full Text] [Related]
24. Spontaneous reports of hypertension leading to hospitalisation in association with rofecoxib, celecoxib, nabumetone and oxaprozin.
Brinker A; Goldkind L; Bonnel R; Beitz J
Drugs Aging; 2004; 21(7):479-84. PubMed ID: 15132714
[TBL] [Abstract][Full Text] [Related]
25. Prevention of nonsteroidal inflammatory drug-induced urticaria and/or angioedema.
Nosbaum A; Braire-Bourrel M; Dubost R; Faudel A; Parat S; Nicolas JF; Bérard F
Ann Allergy Asthma Immunol; 2013 Apr; 110(4):263-6. PubMed ID: 23535090
[TBL] [Abstract][Full Text] [Related]
26. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
27. Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Asero R
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):187-9. PubMed ID: 16937749
[TBL] [Abstract][Full Text] [Related]
28. Provocation tests with the offending nonsteroidal anti-inflammatory drugs in patients with urticaria/angioedema reactions.
Zisa G; Riccobono F; Bommarito L; D'Antonio C; Calamari AM; Poppa M; Moschella MA; Di Pietrantonj C; Galimberti M
Allergy Asthma Proc; 2012; 33(5):421-6. PubMed ID: 23026184
[TBL] [Abstract][Full Text] [Related]
29. Intolerance reactions due to the selective cyclooxygenase type II inhibitors rofecoxib and celecoxib. Results of oral provocation tests in patients with NSAID hypersensitivity.
Kruse R; Ruzicka T; Grewe M
Acta Derm Venereol; 2003; 83(3):183-5. PubMed ID: 12816152
[TBL] [Abstract][Full Text] [Related]
30. NSAID-sensitive patients tolerate rofecoxib.
Valero A; Baltasar M; Enrique E; Pau L; Dordal MT; Cisteró A; Martí E; Picado C
Allergy; 2002 Dec; 57(12):1214-5. PubMed ID: 12464059
[No Abstract] [Full Text] [Related]
31. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data.
Layton D; Heeley E; Hughes K; Shakir SA
Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537
[TBL] [Abstract][Full Text] [Related]
32. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):154-8. PubMed ID: 16136765
[TBL] [Abstract][Full Text] [Related]
33. Safety of a specific COX-2 inhibitor in aspirin-induced asthma.
Szczeklik A; Nizankowska E; Bochenek G; Nagraba K; Mejza F; Swierczynska M
Clin Exp Allergy; 2001 Feb; 31(2):219-25. PubMed ID: 11251623
[TBL] [Abstract][Full Text] [Related]
34. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
Liccardi G; Salzillo A; Piccolo A; Senna G; Piscitelli E; D'Amato M; D'Amato G
Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):50-3. PubMed ID: 15859361
[TBL] [Abstract][Full Text] [Related]
35. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Laine L; Maller ES; Yu C; Quan H; Simon T
Gastroenterology; 2004 Aug; 127(2):395-402. PubMed ID: 15300570
[TBL] [Abstract][Full Text] [Related]
36. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
Stevenson DD; Simon RA
J Allergy Clin Immunol; 2001 Jul; 108(1):47-51. PubMed ID: 11447381
[TBL] [Abstract][Full Text] [Related]
37. The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials.
Morrison BW; Fricke J; Brown J; Yuan W; Kotey P; Mehlisch D
J Am Dent Assoc; 2000 Dec; 131(12):1729-37. PubMed ID: 11143737
[TBL] [Abstract][Full Text] [Related]
38. Safety of rofecoxib in nonsteroidal anti-inflammatory drugs intolerance.
Muñoz-Bellido FJ; Terrón M; León A
Allergy; 2003 Oct; 58(10):1072-5. PubMed ID: 14510733
[No Abstract] [Full Text] [Related]
39. Oral aspirin challenges in patients with a history of intolerance to single non-steroidal anti-inflammatory drugs.
Asero R
Clin Exp Allergy; 2005 Jun; 35(6):713-6. PubMed ID: 15969659
[TBL] [Abstract][Full Text] [Related]
40. Approaches to the diagnosis and management of patients with a history of nonsteroidal anti-inflammatory drug-related urticaria and angioedema.
Kowalski ML; Woessner K; Sanak M
J Allergy Clin Immunol; 2015 Aug; 136(2):245-51. PubMed ID: 26254051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
